Article Information
History
- March 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Suvimol Niyomnaitham1,2,
- Zheng Quan Toh3,4,
- Patimaporn Wongprompitak5,
- Laddawan Jansarikit6,
- Kanjana Srisutthisamphan7,
- Sompong Sapsutthipas8,
- Yuparat Jantraphakorn7,
- Natthakarn Mingngamsup8,
- Paul V Licciardi3,4 and
- Kulkanya Chokephaibulkit1,9,*
- 1Siriraj Institute of Clinical Research, Bangkok, Thailand
- 2Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 3Murdoch Children’s Research Institute, Parkville, Victoria, Australia
- 4Department of Pediatrics, The University of Melbourne, Parkville, Victoria, Australia
- 5Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 6Health Systems Research Institute (HSRI), Nonthaburi, Thailand
- 7National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science Development Agency (NSTDA), Pathum thani, Thailand
- 8Department of Medical Sciences, Institute of Biological Products, Bangkok, Thailand
- 9Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
- ↵*Corresponding author:
Kulkanya Chokephaibulkit, MD, Professor of Pediatrics, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Siriraj Institute of Clinical Research (SICRES), 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand, Tel: (+66) 2-4141899; Fax: (+66) 2-4128243, E-mail: kulkanya.cho{at}mahidol.ac.th
Posted March 06, 2022.
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac and ChAdOx1 and BNT162b2 plus heterologous BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
